MetaStat, Inc. Featured in Prestigious Scientific Journal – Nature
16 Mayo 2014 - 7:50AM
Access Wire
MONTCLAIR, NJ / ACCESSWIRE / May 16, 2014 / MetaStat,
Inc. (OTCQB: MTST), a life science company focused on understanding
and treating systemic metastasis, announced today that our company
was featured in an article titled, “Cancer caught in the act”
written by Nature, a scientific journal highlighting the
increased use of Intravital imaging used in research to monitor
tumor cells as well as the growth, spread (metastasis) and
treatment of cancer in living animal cells.
Advances in Intravital imaging has given researchers the ability
to use molecular markers to visualize eight different kinds of
cells and structures, including immune-system cells and endothelial
cells that line blood vessels. The Intravital imaging revealed
unusual cellular behavior in macrophages, an immune cell that
usually removes dead cells, engulfs pathogens, stimulates immune
response to fight cancer but can also boost the speed and growth of
a tumor. “Intravital imaging studies showed that macrophages along
with tumor cells and endothelial cells, form a structure that pumps
tumor cells into the bloodstream - a key step in metastasis.” The
process or ‘pump’ found by John Condeelis, Ph.D., along with a team
of researchers at Albert Einstein College of Medicine in New York,
has shown ‘pumps’ to be present in human breast cancer. A 60-person
breast cancer study revealed that individuals with tumors with
higher density of ‘pumps’ were more likely to develop metastasis in
other organs.
MetaStat has licensed this “pump” or MetaSite
Breast(tm) technology and is using it both independently and
in combination with our other diagnostic products, to develop tests
that predict metastatic risk in women with breast cancer. Our
MetaSite Breast(tm) test is the first diagnostic that directly
detects and quantifies the actual mechanisms by which mestastatic
cells disseminate through the blood stream to cause the secondary
(metastatic) tumors that are responsible for 90% of fatalities in
epithelial-based sold tumor cancers. Over 600 women have already
been studied employing this technology and additional clinical
trials are expected to begin by the end of this calendar year with
anticipated commercialization in 2015.
Dr. Heiner Dreismann, head of diagnostics at MetaStat and former
president and chief executive officer of Roche Molecular Systems
with more than 24 years of experience in the health care industry
commented, “We believe that our novel diagnostic technologies based
on our unique understanding of systemic metastasis will offer an
early and reliable prediction and treatment of metastasis in
patients with breast cancer and other solid tumors. Our
MetaSite Breast(tm) test has the potential to allow women and
their doctors to tailor and personalize a treatment approach that
is most appropriate to their needs regarding chemotherapy.”
About MetaStat, Inc.
MetaStat is a life sciences company that develops and
commercialized diagnostic products and novel therapeutics for the
early and reliable prediction and treatment of systemic metastasis,
the process by which cancer spreads from a primary tumor through
the bloodstream to other areas of the body. MetaStat is focused on
breast, prostate, lung and colorectal cancers, where systemic
metastasis is responsible for approximately 90% of all deaths. The
Company’s function-based diagnostic platform technology is based on
the identification and understanding of the pivotal role of the
mena protein and its isoforms, a common pathway for the development
of systemic metastatic disease in all epithelial-based solid
tumors. Both the MetaSite Breast(tm) and MenaCalc(tm) product lines
are designed to accurately stratify patients based on their
individual risk of metastasis and to allow clinicians to better
"customize" cancer treatment decisions by positively identifying
patients with a high-risk of metastasis who need aggressive therapy
and by sparing patients with a low-risk of metastasis from the
harmful side effects and expense of chemotherapy. Additionally, the
MenaBloc™ therapeutic program aims to build upon mena biology and
alternative splicing events as a driver of disease progression to
exploit novel targets that provide precision medicines in
oncology.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of
various factors and other risks, including those set forth in the
Company's Form 10-K filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and the company undertakes
no obligation to update such statements.
Contact
IRTH Communications
Robert Haag
1-866-976-4784
mtst@irthcommunications.com
MetaStat, Inc.
Daniel Schneiderman, Vice President
(212) 608-0827
dan@metastat.com
Source: MetaStat, Inc.
MetaStat (CE) (USOTC:MTST)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
MetaStat (CE) (USOTC:MTST)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024